A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E‐mutated chronic lymphocytic leukemia/small lymphocytic lymphoma

BRAF mutation status is a critical predictive and prognostic biomarker in guiding management of unresectable and metastatic melanoma.¹ We recently observed a case of BRAF V600E‐mutated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intermixed with BRAF V600E wild‐type melanoma reported to harbor BRAF V600E mutation on molecular testing. Our observation underscores the importance of appropriate tumor selection for molecular studies and knowledge of mutational status of co‐existing tumors.

This article is protected by copyright. All rights reserved.

http://bit.ly/2GtcD3A